import{p as B,m as j,d as te,g as V,L as ne,F as ae,f as ie,j as h,H as J,a4 as Ce,n as L,o as i,q as p,D as we,ax as oe,ay as se,r as R,s as W,I as O,O as ke,W as re,_ as xe,V as _e,J as Te,$ as M,E as z,N as Se,X as Ie,a7 as Re,al as Be,v as U,ap as G,aq as Ve,y,ar as Le,as as Ne,B as Ae,C as Pe,z as x,az as Y,x as De,A as Oe}from"./index-Byz-Uhq6.js";import{y as ze,z as Ee,A as He,B as Xe,d as E,V as Fe,C as Ue,D as $e}from"./VBtn-DC8XSDvP.js";import{m as le,_ as We}from"./dimensions-DRFpuysA.js";import{m as Me,b as Ye,u as $,a as je,M as qe,d as Je,V as H}from"./VImg-Vv_5ylml.js";import{V as P}from"./VContainer-CFgxmXTV.js";import{V as K,a as D}from"./VRow-Vqc85rrY.js";import{m as Ge,u as Ke,a as Qe,V as Q}from"./lazy-B-an3MwS.js";/* empty css              */const Ze=B({absolute:Boolean,active:{type:Boolean,default:!0},bgColor:String,bgOpacity:[Number,String],bufferValue:{type:[Number,String],default:0},bufferColor:String,bufferOpacity:[Number,String],clickable:Boolean,color:String,height:{type:[Number,String],default:4},indeterminate:Boolean,max:{type:[Number,String],default:100},modelValue:{type:[Number,String],default:0},opacity:[Number,String],reverse:Boolean,stream:Boolean,striped:Boolean,roundedBar:Boolean,...j(),...ze({location:"top"}),...Me(),...le(),...te()},"VProgressLinear"),et=V()({name:"VProgressLinear",props:Ze(),emits:{"update:modelValue":e=>!0},setup(e,a){var q;let{slots:t}=a;const n=ne(e,"modelValue"),{isRtl:s,rtlClasses:r}=ae(),{themeClasses:o}=ie(e),{locationStyles:m}=Ee(e),{textColorClasses:u,textColorStyles:v}=Ye(e,"color"),{backgroundColorClasses:C,backgroundColorStyles:g}=$(h(()=>e.bgColor||e.color)),{backgroundColorClasses:b,backgroundColorStyles:w}=$(h(()=>e.bufferColor||e.bgColor||e.color)),{backgroundColorClasses:c,backgroundColorStyles:T}=$(e,"color"),{roundedClasses:N}=je(e),{intersectionRef:_,isIntersecting:X}=He(),S=h(()=>parseFloat(e.max)),l=h(()=>parseFloat(e.height)),d=h(()=>J(parseFloat(e.bufferValue)/S.value*100,0,100)),f=h(()=>J(parseFloat(n.value)/S.value*100,0,100)),k=h(()=>s.value!==e.reverse),ge=h(()=>e.indeterminate?"fade-transition":"slide-x-transition"),A=Ce&&((q=window.matchMedia)==null?void 0:q.call(window,"(forced-colors: active)").matches);function fe(I){if(!_.value)return;const{left:ye,right:be,width:F}=_.value.getBoundingClientRect(),pe=k.value?F-I.clientX+(be-F):I.clientX-ye;n.value=Math.round(pe/F*S.value)}return L(()=>i(e.tag,{ref:_,class:["v-progress-linear",{"v-progress-linear--absolute":e.absolute,"v-progress-linear--active":e.active&&X.value,"v-progress-linear--reverse":k.value,"v-progress-linear--rounded":e.rounded,"v-progress-linear--rounded-bar":e.roundedBar,"v-progress-linear--striped":e.striped},N.value,o.value,r.value,e.class],style:[{bottom:e.location==="bottom"?0:void 0,top:e.location==="top"?0:void 0,height:e.active?p(l.value):0,"--v-progress-linear-height":p(l.value),...e.absolute?m.value:{}},e.style],role:"progressbar","aria-hidden":e.active?"false":"true","aria-valuemin":"0","aria-valuemax":e.max,"aria-valuenow":e.indeterminate?void 0:f.value,onClick:e.clickable&&fe},{default:()=>[e.stream&&i("div",{key:"stream",class:["v-progress-linear__stream",u.value],style:{...v.value,[k.value?"left":"right"]:p(-l.value),borderTop:`${p(l.value/2)} dotted`,opacity:parseFloat(e.bufferOpacity),top:`calc(50% - ${p(l.value/4)})`,width:p(100-d.value,"%"),"--v-progress-linear-stream-to":p(l.value*(k.value?1:-1))}},null),i("div",{class:["v-progress-linear__background",A?void 0:C.value],style:[g.value,{opacity:parseFloat(e.bgOpacity),width:e.stream?0:void 0}]},null),i("div",{class:["v-progress-linear__buffer",A?void 0:b.value],style:[w.value,{opacity:parseFloat(e.bufferOpacity),width:p(d.value,"%")}]},null),i(we,{name:ge.value},{default:()=>[e.indeterminate?i("div",{class:"v-progress-linear__indeterminate"},[["long","short"].map(I=>i("div",{key:I,class:["v-progress-linear__indeterminate",I,A?void 0:c.value],style:T.value},null))]):i("div",{class:["v-progress-linear__determinate",A?void 0:c.value],style:[T.value,{width:p(f.value,"%")}]},null)]}),t.default&&i("div",{class:"v-progress-linear__content"},[t.default({value:f.value,buffer:d.value})])]})),{}}}),tt="/assets/company-C4pDpcHc.png",nt=e=>{const{touchstartX:a,touchendX:t,touchstartY:n,touchendY:s}=e,r=.5,o=16;e.offsetX=t-a,e.offsetY=s-n,Math.abs(e.offsetY)<r*Math.abs(e.offsetX)&&(e.left&&t<a-o&&e.left(e),e.right&&t>a+o&&e.right(e)),Math.abs(e.offsetX)<r*Math.abs(e.offsetY)&&(e.up&&s<n-o&&e.up(e),e.down&&s>n+o&&e.down(e))};function at(e,a){var n;const t=e.changedTouches[0];a.touchstartX=t.clientX,a.touchstartY=t.clientY,(n=a.start)==null||n.call(a,{originalEvent:e,...a})}function it(e,a){var n;const t=e.changedTouches[0];a.touchendX=t.clientX,a.touchendY=t.clientY,(n=a.end)==null||n.call(a,{originalEvent:e,...a}),nt(a)}function ot(e,a){var n;const t=e.changedTouches[0];a.touchmoveX=t.clientX,a.touchmoveY=t.clientY,(n=a.move)==null||n.call(a,{originalEvent:e,...a})}function st(){let e=arguments.length>0&&arguments[0]!==void 0?arguments[0]:{};const a={touchstartX:0,touchstartY:0,touchendX:0,touchendY:0,touchmoveX:0,touchmoveY:0,offsetX:0,offsetY:0,left:e.left,right:e.right,up:e.up,down:e.down,start:e.start,move:e.move,end:e.end};return{touchstart:t=>at(t,a),touchend:t=>it(t,a),touchmove:t=>ot(t,a)}}function rt(e,a){var m;const t=a.value,n=t!=null&&t.parent?e.parentElement:e,s=(t==null?void 0:t.options)??{passive:!0},r=(m=a.instance)==null?void 0:m.$.uid;if(!n||!r)return;const o=st(a.value);n._touchHandlers=n._touchHandlers??Object.create(null),n._touchHandlers[r]=o,oe(o).forEach(u=>{n.addEventListener(u,o[u],s)})}function lt(e,a){var r,o;const t=(r=a.value)!=null&&r.parent?e.parentElement:e,n=(o=a.instance)==null?void 0:o.$.uid;if(!(t!=null&&t._touchHandlers)||!n)return;const s=t._touchHandlers[n];oe(s).forEach(m=>{t.removeEventListener(m,s[m])}),delete t._touchHandlers[n]}const ce={mounted:rt,unmounted:lt},ue=Symbol.for("vuetify:v-window"),de=Symbol.for("vuetify:v-window-group"),he=B({continuous:Boolean,nextIcon:{type:[Boolean,String,Function,Object],default:"$next"},prevIcon:{type:[Boolean,String,Function,Object],default:"$prev"},reverse:Boolean,showArrows:{type:[Boolean,String],validator:e=>typeof e=="boolean"||e==="hover"},touch:{type:[Object,Boolean],default:void 0},direction:{type:String,default:"horizontal"},modelValue:null,disabled:Boolean,selectedClass:{type:String,default:"v-window-item--active"},mandatory:{type:[Boolean,String],default:"force"},...j(),...le(),...te()},"VWindow"),Z=V()({name:"VWindow",directives:{Touch:ce},props:he(),emits:{"update:modelValue":e=>!0},setup(e,a){let{slots:t}=a;const{themeClasses:n}=ie(e),{isRtl:s}=ae(),{t:r}=se(),o=Xe(e,de),m=R(),u=h(()=>s.value?!e.reverse:e.reverse),v=W(!1),C=h(()=>{const l=e.direction==="vertical"?"y":"x",f=(u.value?!v.value:v.value)?"-reverse":"";return`v-window-${l}${f}-transition`}),g=W(0),b=R(void 0),w=h(()=>o.items.value.findIndex(l=>o.selected.value.includes(l.id)));O(w,(l,d)=>{const f=o.items.value.length,k=f-1;f<=2?v.value=l<d:l===k&&d===0?v.value=!0:l===0&&d===k?v.value=!1:v.value=l<d}),ke(ue,{transition:C,isReversed:v,transitionCount:g,transitionHeight:b,rootRef:m});const c=h(()=>e.continuous||w.value!==0),T=h(()=>e.continuous||w.value!==o.items.value.length-1);function N(){c.value&&o.prev()}function _(){T.value&&o.next()}const X=h(()=>{const l=[],d={icon:s.value?e.nextIcon:e.prevIcon,class:`v-window__${u.value?"right":"left"}`,onClick:o.prev,"aria-label":r("$vuetify.carousel.prev")};l.push(c.value?t.prev?t.prev({props:d}):i(E,d,null):i("div",null,null));const f={icon:s.value?e.prevIcon:e.nextIcon,class:`v-window__${u.value?"left":"right"}`,onClick:o.next,"aria-label":r("$vuetify.carousel.next")};return l.push(T.value?t.next?t.next({props:f}):i(E,f,null):i("div",null,null)),l}),S=h(()=>e.touch===!1?e.touch:{...{left:()=>{u.value?N():_()},right:()=>{u.value?_():N()},start:d=>{let{originalEvent:f}=d;f.stopPropagation()}},...e.touch===!0?{}:e.touch});return L(()=>re(i(e.tag,{ref:m,class:["v-window",{"v-window--show-arrows-on-hover":e.showArrows==="hover"},n.value,e.class],style:e.style},{default:()=>{var l,d;return[i("div",{class:"v-window__container",style:{height:b.value}},[(l=t.default)==null?void 0:l.call(t,{group:o}),e.showArrows!==!1&&i("div",{class:"v-window__controls"},[X.value])]),(d=t.additional)==null?void 0:d.call(t,{group:o})]}}),[[xe("touch"),S.value]])),{group:o}}}),ct=B({color:String,cycle:Boolean,delimiterIcon:{type:_e,default:"$delimiter"},height:{type:[Number,String],default:500},hideDelimiters:Boolean,hideDelimiterBackground:Boolean,interval:{type:[Number,String],default:6e3,validator:e=>Number(e)>0},progress:[Boolean,String],verticalDelimiters:[Boolean,String],...he({continuous:!0,mandatory:"force",showArrows:!0})},"VCarousel"),ut=V()({name:"VCarousel",props:ct(),emits:{"update:modelValue":e=>!0},setup(e,a){let{slots:t}=a;const n=ne(e,"modelValue"),{t:s}=se(),r=R();let o=-1;O(n,u),O(()=>e.interval,u),O(()=>e.cycle,v=>{v?u():window.clearTimeout(o)}),Te(m);function m(){!e.cycle||!r.value||(o=window.setTimeout(r.value.group.next,+e.interval>0?+e.interval:6e3))}function u(){window.clearTimeout(o),window.requestAnimationFrame(m)}return L(()=>{const v=Z.filterProps(e);return i(Z,z({ref:r},v,{modelValue:n.value,"onUpdate:modelValue":C=>n.value=C,class:["v-carousel",{"v-carousel--hide-delimiter-background":e.hideDelimiterBackground,"v-carousel--vertical-delimiters":e.verticalDelimiters},e.class],style:[{height:p(e.height)},e.style]}),{default:t.default,additional:C=>{let{group:g}=C;return i(M,null,[!e.hideDelimiters&&i("div",{class:"v-carousel__controls",style:{left:e.verticalDelimiters==="left"&&e.verticalDelimiters?0:"auto",right:e.verticalDelimiters==="right"?0:"auto"}},[g.items.value.length>0&&i(Fe,{defaults:{VBtn:{color:e.color,icon:e.delimiterIcon,size:"x-small",variant:"text"}},scoped:!0},{default:()=>[g.items.value.map((b,w)=>{const c={id:`carousel-item-${b.id}`,"aria-label":s("$vuetify.carousel.ariaLabel.delimiter",w+1,g.items.value.length),class:["v-carousel__controls__item",g.isSelected(b.id)&&"v-btn--active"],onClick:()=>g.select(b.id,!0)};return t.item?t.item({props:c,item:b}):i(E,z(b,c),null)})]})]),e.progress&&i(et,{class:"v-carousel__progress",color:typeof e.progress=="string"?e.progress:void 0,modelValue:(g.getItemIndex(n.value)+1)/g.items.value.length*100},null)])},prev:t.prev,next:t.next})}),{}}}),me=B({reverseTransition:{type:[Boolean,String],default:void 0},transition:{type:[Boolean,String],default:void 0},...j(),...Ue(),...Ge()},"VWindowItem"),ee=V()({name:"VWindowItem",directives:{Touch:ce},props:me(),emits:{"group:selected":e=>!0},setup(e,a){let{slots:t}=a;const n=Se(ue),s=$e(e,de),{isBooted:r}=Ke();if(!n||!s)throw new Error("[Vuetify] VWindowItem must be used inside VWindow");const o=W(!1),m=h(()=>r.value&&(n.isReversed.value?e.reverseTransition!==!1:e.transition!==!1));function u(){!o.value||!n||(o.value=!1,n.transitionCount.value>0&&(n.transitionCount.value-=1,n.transitionCount.value===0&&(n.transitionHeight.value=void 0)))}function v(){var c;o.value||!n||(o.value=!0,n.transitionCount.value===0&&(n.transitionHeight.value=p((c=n.rootRef.value)==null?void 0:c.clientHeight)),n.transitionCount.value+=1)}function C(){u()}function g(c){o.value&&Re(()=>{!m.value||!o.value||!n||(n.transitionHeight.value=p(c.clientHeight))})}const b=h(()=>{const c=n.isReversed.value?e.reverseTransition:e.transition;return m.value?{name:typeof c!="string"?n.transition.value:c,onBeforeEnter:v,onAfterEnter:u,onEnterCancelled:C,onBeforeLeave:v,onAfterLeave:u,onLeaveCancelled:C,onEnter:g}:!1}),{hasContent:w}=Qe(e,s.isSelected);return L(()=>i(qe,{transition:b.value,disabled:!r.value},{default:()=>{var c;return[re(i("div",{class:["v-window-item",s.selectedClass.value,e.class],style:e.style},[w.value&&((c=t.default)==null?void 0:c.call(t))]),[[Ie,s.isSelected.value]])]}})),{groupItem:s}}}),dt=B({...Je(),...me()},"VCarouselItem"),ht=V()({name:"VCarouselItem",inheritAttrs:!1,props:dt(),setup(e,a){let{slots:t,attrs:n}=a;L(()=>{const s=H.filterProps(e),r=ee.filterProps(e);return i(ee,z({class:["v-carousel-item",e.class]},r),{default:()=>[i(H,z(n,s),t)]})})}}),ve=e=>(Ae("data-v-d38e44a8"),e=e(),Pe(),e),mt={class:"text-sm-h5 text-h6 font-weight-bold"},vt=["innerHTML"],gt={class:"pt-2 text-right"},ft=ve(()=>x("h4",{class:"text-sm-h5 text-h6 font-weight-bold"},"About us",-1)),yt=ve(()=>x("p",{class:"pt-4"},[Y(" The "),x("span",{class:"text-sm-h6 font-weight-bold"},"JIACAI Foundation"),Y(" was established in November 2018 in loving memory of a cherished grandpa who tragically lost his battle with Non-Small Cell Lung Cancer (NSCLC). His passing left a profound impact on our lives and inspired us to take action against this devastating disease."),x("br")],-1)),bt=Be({__name:"index",setup(e){R([{src:new URL("/assets/index_carousel1-DJqHTgIS.png",import.meta.url).href,title:"Therapeutic cancer vaccine",content:"The University of Oxford is at the forefront of developing mRNA vaccines for the treatment of non-small cell lung cancer (NSCLC). Recent research at Oxford has explored the potential of mRNA vaccines as a novel therapeutic approach for treating NSCLC. Unlike traditional vaccines that focus on preventing infections, mRNA vaccines for cancer are designed to trigger an immune response against cancer cells. Researchers atOxford have been developing mRNA vaccines that encode specific tumor associated antigens found on the surface of NSCLC cells, allowing the immune system to recognize and attack the cancer cells more effectively. One key study involves the use of mRNA technology to deliver the genetic blueprint for proteins that are overexpressed in NSCLC, such as the HER2 receptor, stimulating the immune system to target and destroy tumor cells. In clinical trials, these vaccines have shown promising results, particularly in combination with checkpoint inhibitors like PD-1/PD-L1 blockers, which enhance the immune response further. A phase 1/2 clinical trial by BioNTech in collaboration with Oxford has demonstrated that mRNA vaccines can provoke strong immune reactions in NSCLC patients, leading to some patients experiencing reduced tumor sizes or stable disease. While still in early stages, this approach holds significant promise for providing a personalized treatment option, especially for patients with advanced or metastatic lung cancer where conventional treatments may be less effective."},{src:new URL("/assets/index_carousel2-BBoLe3gB.png",import.meta.url).href,title:"Early detection",content:"In the UK, a cutting-edge research project is exploring the use of artificial intelligence (AI) to detect early-stage lung cancer, particularly focusing on non-small cell lung cancer (NSCLC). Leveraging advanced machine learning algorithms, the initiative aims to analyze medical imaging data, such as CT scans, to identify subtle patterns and biomarkers indicative of early tumor growth that might otherwise go unnoticed by traditional methods. By training AI systems on large datasets of medical images and patient information, researchers are developing AI tools that can assist clinicians in making more accurate diagnoses, leading to earlier intervention and improved survival rates. These AI applications are also being integrated with clinical workflows to provide real-time, data-driven insights, reducing the time to diagnosis and enhancing personalized treatment options for patients. The research highlights the potential of AI to transform lung cancer detection in the UK, making it faster, more precise, and accessible."},{src:new URL("/assets/index_carousel3-BPX9nPlm.png",import.meta.url).href,title:"Nanobiocensors",content:"A recent research initiative led by a renowned university focused on developing advanced nano biosensors for the treatment of non-small cell lung cancer (NSCLC). The project explores the integration of nanotechnology and biosensing to improve early detection, monitoring, and targeted therapy of NSCLC. Researchers have engineered nanosensors that can detect specific biomarkers associated with the cancer’s progression, providing real-time diagnostic capabilities. These sensors work by binding to molecular markers on the cancer cells, emitting signals that are easily detectable through non-invasive techniques. This approach not only enhances the sensitivity and specificity of cancer detection but also offers potential for personalized treatments by identifying precise therapeutic targets. The research aims to revolutionize NSCLC management by enabling more effective, timely, and less invasive interventions."},{src:new URL("/assets/index_carousel4-fV2haSAV.png",import.meta.url).href,title:"CRT + PD1 inhibitors",content:"Cancer research has witnessed remarkable advancements in recent years, particularly through the exploration of therapies like Chimeric Antigen Receptor T-cell (CAR-T) therapy and immune checkpoint inhibitors, such as PD-1 inhibitors. CAR-T therapy involves engineering a patient’s own T-cells to target and destroy cancer cells, while PD-1 inhibitors work by blocking the PD-1 protein on T-cells, allowing the immune system to better recognize and attack cancer cells. The Oxford experiment stands out for its novel approach to combining these two treatments, aiming to enhance therapeutic outcomes by targeting cancer in a more comprehensive way. This groundbreaking research has the potential to significantly improve patient survival rates and reduce relapse. JCF is proud to support such pioneering work, offering grants to researchers exploring innovative cancer therapies, including this Oxford-led initiative, to accelerate their efforts and bring transformative treatments to patients worldwide."}]);const a=R([]);return a.value=[{path:"one",caseImage:new URL("/assets/index_carousel1-DJqHTgIS.png",import.meta.url).href,caseTitle:"Therapeutic cancer vaccine",caseContent:"The University of Oxford is at the forefront of developing mRNA vaccines for the treatment of non-small cell lung cancer (NSCLC). Recent research at Oxford has explored the potential of mRNA vaccines as a novel therapeutic approach for treating NSCLC. Unlike traditional vaccines that focus on preventing infections, mRNA vaccines for cancer are designed to trigger an immune response against cancer cells. Researchers atOxford have been developing mRNA vaccines that encode specific tumor associated antigens found on the surface of NSCLC cells, allowing the immune system to recognize and attack the cancer cells more effectively. One key study involves the use of mRNA technology to deliver the genetic blueprint for proteins that are overexpressed in NSCLC, such as the HER2 receptor, stimulating the immune system to target and destroy tumor cells. In clinical trials, these vaccines have shown promising results, particularly in combination with checkpoint inhibitors like PD-1/PD-L1 blockers, which enhance the immune response further. A phase 1/2 clinical trial by BioNTech in collaboration with Oxford has demonstrated that mRNA vaccines can provoke strong immune reactions in NSCLC patients, leading to some patients experiencing reduced tumor sizes or stable disease. While still in early stages, this approach holds significant promise for providing a personalized treatment option, especially for patients with advanced or metastatic lung cancer where conventional treatments may be less effective."},{path:"two",caseImage:new URL("/assets/index_carousel2-BBoLe3gB.png",import.meta.url).href,caseTitle:"Early detection",caseContent:"In the UK, a cutting-edge research project is exploring the use of artificial intelligence (AI) to detect early-stage lung cancer, particularly focusing on non-small cell lung cancer (NSCLC). Leveraging advanced machine learning algorithms, the initiative aims to analyze medical imaging data, such as CT scans, to identify subtle patterns and biomarkers indicative of early tumor growth that might otherwise go unnoticed by traditional methods. By training AI systems on large datasets of medical images and patient information, researchers are developing AI tools that can assist clinicians in making more accurate diagnoses, leading to earlier intervention and improved survival rates. These AI applications are also being integrated with clinical workflows to provide real-time, data-driven insights, reducing the time to diagnosis and enhancing personalized treatment options for patients. The research highlights the potential of AI to transform lung cancer detection in the UK, making it faster, more precise, and accessible."},{path:"three",caseImage:new URL("/assets/index_carousel3-BPX9nPlm.png",import.meta.url).href,caseTitle:"Nanobiocensors",caseContent:"A recent research initiative led by a renowned university focused on developing advanced nano biosensors for the treatment of non-small cell lung cancer (NSCLC). The project explores the integration of nanotechnology and biosensing to improve early detection, monitoring, and targeted therapy of NSCLC. Researchers have engineered nanosensors that can detect specific biomarkers associated with the cancer’s progression, providing real-time diagnostic capabilities. These sensors work by binding to molecular markers on the cancer cells, emitting signals that are easily detectable through non-invasive techniques. This approach not only enhances the sensitivity and specificity of cancer detection but also offers potential for personalized treatments by identifying precise therapeutic targets. The research aims to revolutionize NSCLC management by enabling more effective, timely, and less invasive interventions."},{path:"four",caseImage:new URL("/assets/index_carousel4-fV2haSAV.png",import.meta.url).href,caseTitle:"CRT + PD1 inhibitors",caseContent:"Cancer research has witnessed remarkable advancements in recent years, particularly through the exploration of therapies like Chimeric Antigen Receptor T-cell (CAR-T) therapy and immune checkpoint inhibitors, such as PD-1 inhibitors. CAR-T therapy involves engineering a patient’s own T-cells to target and destroy cancer cells, while PD-1 inhibitors work by blocking the PD-1 protein on T-cells, allowing the immune system to better recognize and attack cancer cells. The Oxford experiment stands out for its novel approach to combining these two treatments, aiming to enhance therapeutic outcomes by targeting cancer in a more comprehensive way. This groundbreaking research has the potential to significantly improve patient survival rates and reduce relapse. JCF is proud to support such pioneering work, offering grants to researchers exploring innovative cancer therapies, including this Oxford-led initiative, to accelerate their efforts and bring transformative treatments to patients worldwide."}],(t,n)=>(U(),G(M,null,[Ve("",!0),i(P,null,{default:y(()=>[i(ut,{class:"example-carousel",color:"blue-darken-2","hide-delimiter-background":"","show-arrows":!1,cycle:""},{default:y(()=>[(U(!0),G(M,null,Le(Ne(a),(s,r)=>(U(),De(ht,{key:r,cover:"",transition:!1},{default:y(()=>[i(K,null,{default:y(()=>[i(D,{sm:"6",cols:"12"},{default:y(()=>[i(H,{class:"bg-surface-light rounded-lg",height:"320",cover:"",src:s.caseImage},null,8,["src"])]),_:2},1024),i(D,{sm:"6",cols:"12"},{default:y(()=>[i(P,{class:"bg-shades-white rounded-lg"},{default:y(()=>[x("h4",mt,Oe(s.caseTitle),1),i(Q,{class:"my-2",thickness:"2"}),x("p",{class:"text-line-8",innerHTML:s.caseContent},null,8,vt),x("p",gt,[i(E,{class:"bg-blue-lighten-1",variant:"tonal","append-icon":"mdi-arrow-right",rounded:"xl",to:`/research/${s.path}`},{default:y(()=>[Y("Detail ")]),_:2},1032,["to"])])]),_:2},1024)]),_:2},1024)]),_:2},1024)]),_:2},1024))),128))]),_:1})]),_:1}),i(P,null,{default:y(()=>[i(K,null,{default:y(()=>[i(D,{class:"ga-8",sm:"6",cols:"12","order-sm":"1",order:"2"},{default:y(()=>[i(P,{class:"bg-shades-white rounded-lg"},{default:y(()=>[ft,i(Q,{class:"my-2",thickness:"2"}),yt]),_:1})]),_:1}),i(D,{sm:"6",cols:"12","order-sm":"2",order:"1"},{default:y(()=>[i(H,{class:"bg-white rounded-lg mb-4",height:"250",src:tt})]),_:1})]),_:1})]),_:1})],64))}}),It=We(bt,[["__scopeId","data-v-d38e44a8"]]);export{It as default};
